» Articles » PMID: 36586226

Co-VAN Study: COVID-19 Vaccine Associated Neurological Diseases- an Experience from an Apex Neurosciences Centre and Review of the Literature

Abstract

Background: Recent studies have shown various neurological adverse events associated with COVID-19 vaccine.

Objective: We aimed to retrospectively review and report the neurological diseases temporally associated with COVID-19 vaccine.

Methods: We performed a retrospective chart review of admitted patients from 1st February 2021 to 30th June 2022. A total of 4672 medical records were reviewed of which 51 cases were identified to have neurological illness temporally associated with COVID-19 vaccination.

Results: Out of 51 cases, 48 had probable association with COVID-19 vaccination while three had possible association. Neurological spectrum included CNS demyelination (n = 39, 76.5 %), Guillain-Barré-syndrome (n = 3, 5.9 %), stroke (n = 6, 11.8 %), encephalitis (n = 2, 3.9 %) and myositis (n = 1, 2.0 %). Female gender had a greater predisposition (F:M, 1.13:1). Neurological events were more commonly encountered after the first-dose (n = 37, 72.5%). The mean latency to onset of symptoms was 13.2 ± 10.7 days after the last dose of vaccination. COVIShield (ChAdOx1) was the most commonly administered vaccine (n = 43, 84.3 %). Majority of the cases with demyelination were seronegative (n = 23, 59.0 %) which was followed by anti-Myelin oligodendrocyte-glycoprotein associated demyelination (MOGAD) (n = 11, 28.2 %) and Neuromyelitis optica (NMOSD) (n = 5, 12.8 %). Out of 6 Stroke cases, 2 cases (33.3 %) had thrombocytopenia and coagulopathy. At discharge, 25/51 (49.0 %) of the cases had favourable outcome (mRS 0 to 1). Among six patients of stroke, only one of them had favourable outcome.

Conclusion: In this series, we describe the wide variety of neurological syndromes temporally associated with COVID-19 vaccination. Further studies with larger sample size and longer duration of follow-up are needed to prove or disprove causality association of these syndromes with COVID-19 vaccination.

Citing Articles

Myelin Oligodendrocyte Glycoprotein G Antibody-Positive Paraneoplastic Myelopathy in Seminoma: A Case Report and Literature Review.

Hamid U, Rissardo J, Alviz L, Caprara A, Franada T Neurohospitalist. 2024; :19418744241288288.

PMID: 39544263 PMC: 11559457. DOI: 10.1177/19418744241288288.


Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.

Liu L, Zhou C, Jiang H, Wei H, Zhou Y, Zhou C Front Med. 2024; 17(6):1047-1067.

PMID: 38165535 DOI: 10.1007/s11684-023-1041-7.


Association of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease with Coronavirus Disease 2019 Vaccination and Infection: A Case Report of Cortical Encephalitis and Transverse Myelitis Relapse.

Himeno Y, Tateishi T, Irie K, Ueno S, Morimitsu M, Mizoguchi S Intern Med. 2023; 62(23):3549-3554.

PMID: 37743511 PMC: 10749814. DOI: 10.2169/internalmedicine.2471-23.

References
1.
Azumagawa K, Nomura S, Shigeri Y, Sargent Jones L, Sato D, Nakashima I . Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy. Brain Dev. 2016; 38(7):690-3. DOI: 10.1016/j.braindev.2016.02.004. View

2.
Nassar M, Chung H, Dhayaparan Y, Nyein A, Acevedo B, Chicos C . COVID-19 vaccine induced rhabdomyolysis: Case report with literature review. Diabetes Metab Syndr. 2021; 15(4):102170. PMC: 8205294. DOI: 10.1016/j.dsx.2021.06.007. View

3.
van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sanchez van Kammen M, Heldner M, Jood K . Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. Eur J Neurol. 2021; 29(1):339-344. PMC: 8652752. DOI: 10.1111/ene.15113. View

4.
Scott J, Anderson J, Mallak N, Beitinjaneh B, Wei K, Otaki F . Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination. Am J Gastroenterol. 2021; 116(11):2300. DOI: 10.14309/ajg.0000000000001354. View

5.
Ibrahim Ismail I, Salama S . A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2021; 362:577765. PMC: 8577051. DOI: 10.1016/j.jneuroim.2021.577765. View